Alex Rodriguez TRT: Compounded vs. Branded Testosterone, What's Most Likely

What Alex Rodriguez Was Actually Documented Using

Rodriguez's hormone history is not speculative. Two separate, documented events establish it.

The first was his 2003 survey test, which MLB later disclosed showed testosterone and primobolan, an anabolic steroid derived from dihydrotestosterone. The second was the 2014 Biogenesis of America investigation, in which clinic founder Tony Bosch alleged supplying Rodriguez with testosterone, human growth hormone (HGH), peptides including IGF-1, and other compounds. MLB's arbitration panel found the evidence credible and upheld the 162-game suspension.

The Biogenesis Substances

Bosch's clinic did not dispense FDA-approved branded products. Biogenesis operated outside licensed pharmacy channels, meaning the testosterone supplied was effectively compounded or raw-material based, with no Certificate of Analysis verified by the FDA [1].

The FDA's guidance on compounding makes clear that drugs produced outside the 503A/503B framework lack the manufacturing controls, sterility testing, and potency verification required of approved products [2]. What Bosch provided was closer to the gray or black market than to a licensed 503B outsourcing facility.

Primobolan: A Black-Market Marker

Primobolan (methenolone) has no current FDA approval in any form in the United States [3]. Its presence in Rodriguez's 2003 sample is the strongest signal that the compounds he used came from outside regulated pharmacy channels entirely. A clinician prescribing legitimate TRT has no legal pathway to prescribe primobolan in the U.S.

Compounded vs. Branded Testosterone: The Clinical Distinction

For patients today, the compounded-vs.-branded question is not an abstract one. It affects potency, sterility, insurance coverage, and legal standing under state pharmacy law.

What "Compounded" Actually Means

A licensed 503A compounding pharmacy can prepare testosterone for an individual patient under a valid prescription. Common preparations include testosterone cypionate 200 mg/mL in cottonseed or sesame oil, testosterone propionate blends, sublingual troches (typically 25 to 50 mg), and transdermal creams in concentrations not available commercially [4].

The FDA does not approve or inspect 503A pharmacies on the same schedule as drug manufacturers. A 2023 FDA report found that roughly 23% of compounded sterile preparations inspected had significant quality deficiencies [5]. That figure does not mean compounded testosterone is uniformly unsafe, but it does mean the patient bears more variability risk than with a branded product manufactured under Current Good Manufacturing Practices (cGMP).

What "Branded" Means

Branded testosterone products approved by the FDA include:

• Testosterone cypionate injection (Depo-Testosterone, Pfizer): 100 mg/mL and 200 mg/mL vials, IM or subcutaneous
• Testosterone enanthate injection (Xyosted): 50, 75, or 100 mg subcutaneous autoinjector weekly
• AndroGel 1.62% (AbbVie): transdermal gel, 20.25 mg or 40.5 mg per actuation
• Aveed (Endo): testosterone undecanoate 750 mg IM, dosed at 0 weeks, 4 weeks, then every 10 weeks
• Natesto (Acerus): 4.5% nasal gel, 11 mg per nostril three times daily

Each carries a full New Drug Application (NDA), FDA-reviewed labeling, and cGMP manufacturing oversight [6].

Pharmacokinetic Comparison

Testosterone cypionate (branded Depo-Testosterone) and its compounded counterpart share the same active moiety, but branded vials must meet USP potency standards of 90 to 110% of labeled strength. A 2017 study analyzing compounded testosterone preparations found potency ranging from 68.2% to 127.5% of labeled concentration across samples from 12 pharmacies [7]. That range matters clinically: a patient targeting a trough of 500 ng/dL could end up anywhere from 340 to 640 ng/dL on the same nominal dose.

What Protocol Rodriguez Was Most Likely Using

Given the documented Biogenesis menu and what sports-performance medicine literature describes for high-level athletes in that era, a plausible Rodriguez-era protocol would have combined multiple agents rather than a simple TRT replacement dose. The framework below is not a prescription; it is a clinical reconstruction based on publicly available arbitration records and sports-doping pharmacology literature.

Phase 1: Base Androgen (Off-Season)

Testosterone in an injectable ester form, most likely testosterone cypionate or enanthate at doses exceeding standard TRT (which the Endocrine Society defines as targeting mid-normal range, approximately 400 to 700 ng/dL) [8]. Performance-oriented misuse in baseball has historically involved 200 to 600 mg per week, doses that produce supraphysiologic serum levels well above 1,000 ng/dL.

At those concentrations, aromatization to estradiol accelerates substantially. Without an aromatase inhibitor, a user at 400 mg/week testosterone could expect estradiol levels above 60 pg/mL, with attendant gynecomastia risk [9]. Bosch's alleged protocol reportedly included anastrozole or exemestane for estrogen management.

Phase 2: Peptides and Growth Factors

The Biogenesis records, as reported in arbitration proceedings, referenced IGF-1 (insulin-like growth factor 1) and HGH. Neither is FDA-approved for athletic performance enhancement. HGH (somatropin) is approved for adult-onset GHD and specific wasting conditions, not for supraphysiologic use in healthy athletes [10].

Peptides such as CJC-1295 and GHRP-6, which stimulate endogenous GH release, are not FDA-approved for any indication and are not legally available through licensed U.S. Pharmacies [11].

Phase 3: In-Season Microdosing or Washout

The 2003 positive test occurred during the survey year, suggesting Rodriguez either did not taper before testing or misjudged detection windows. Modern isotope-ratio mass spectrometry (IRMS) can distinguish exogenous testosterone from endogenous testosterone by carbon-13 to carbon-12 ratios, regardless of the testosterone-to-epitestosterone (T/E) ratio. WADA's IRMS methodology can flag exogenous testosterone use up to three weeks post-injection for long-ester forms [12].

Why Athletes Choose Compounded Over Branded (and the Risks)

The appeal of compounded testosterone for performance use rather than therapeutic use comes down to three factors: dose flexibility, formulation customization, and, in illicit cases, traceability avoidance.

Dose Flexibility

Branded injectable testosterone cypionate is available at 100 mg/mL and 200 mg/mL. A compounding pharmacy can produce 250 mg/mL, 300 mg/mL, or higher concentrations, reducing injection volume for the same dose. That matters for athletes injecting twice weekly or more.

Formulation Options Not Commercially Available

Sublingual testosterone troches (25 to 50 mg) and buccal preparations offer rapid absorption without injection, though their pharmacokinetics are less predictable. A pharmacokinetic review published in the Journal of Clinical Endocrinology and Metabolism found that sublingual testosterone produced peak serum levels within 30 to 60 minutes but returned to baseline within 3 to 4 hours, making steady-state difficult to maintain [13].

Transdermal testosterone creams at concentrations of 10 to 20% are not commercially available but can be compounded. Transfer risk to partners and children is a documented concern for all transdermal forms; the FDA added a black-box warning to AndroGel specifically addressing secondary exposure in 2009 [14].

The Sterility and Potency Risk

Compounded injectables carry a sterility burden that branded vials do not. The 2012 fungal meningitis outbreak linked to contaminated compounded methylprednisolone (724 cases, 64 deaths) prompted Congress to pass the Drug Quality and Security Act of 2013, which created the 503B outsourcing facility category [15]. Licensed 503B facilities must meet cGMP standards and submit to FDA inspection. Patients using compounded testosterone should confirm their pharmacy holds 503B status or is a licensed 503A pharmacy operating under a valid individual prescription.

What Legitimate TRT Looks Like Today: Endocrine Society Standards

Legitimate testosterone replacement is reserved for men with symptomatic hypogonadism confirmed by two morning serum testosterone draws below 300 ng/dL, per the 2018 Endocrine Society Clinical Practice Guideline [8].

The guideline states: "We recommend against making a diagnosis of androgen deficiency in men with morning serum testosterone levels above 400 ng/dL." That single threshold eliminates most healthy athletes from medical eligibility for any form of testosterone therapy.

Baseline Workup Before Any TRT

A proper pre-treatment evaluation includes:

• Two fasting morning total testosterone levels (before 10 a.m.)
• LH and FSH to distinguish primary from secondary hypogonadism
• Prolactin if LH/FSH are low (to rule out pituitary adenoma)
• Hematocrit (testosterone raises erythropoiesis; hematocrit above 54% requires dose reduction or cessation) [8]
• PSA in men over 40 (testosterone is contraindicated in active or suspected prostate cancer)

Monitoring on TRT

Once therapy begins, serum testosterone should be measured 3 to 6 months after initiation, targeting mid-normal range (400 to 700 ng/dL). Hematocrit should be checked at 3 months, 6 months, and annually. A meta-analysis of 35 randomized controlled trials (N=5,601) found that testosterone therapy increased hematocrit by a mean of 3.2 percentage points versus placebo, with polycythemia occurring in 3.9% of treated men vs. 0.7% on placebo [16].

Compounded Testosterone: When It Makes Clinical Sense

Compounded testosterone is not inherently problematic when used within a legitimate therapeutic framework. Three scenarios support its use over branded products.

First, patients who cannot tolerate commercially available vehicles (e.g., sesame oil allergy with Depo-Testosterone) may need a compounded formulation in an alternative carrier such as grapeseed or cottonseed oil.

Second, patients requiring doses that fall outside commercially available strengths (for example, subcutaneous testosterone cypionate at 40 mg twice weekly for a man with secondary hypogonadism) may find compounded preparations more practical than splitting branded vials.

Third, cost. Depo-Testosterone 200 mg/mL 10 mL vials list at approximately $120, $180 per vial under GoodRx pricing, but compounded testosterone cypionate from a 503A pharmacy may cost $40, $80 for an equivalent volume. For uninsured patients, that differential is clinically relevant.

The Endocrine Society's 2018 guideline does not prohibit compounded testosterone but notes that "FDA-approved formulations are preferred when available and affordable" [8].

Detection, Anti-Doping, and the Legal Record

Rodriguez's situation illustrates how anti-doping science has advanced. The 2003 survey test used immunoassay and T/E ratio methods that WADA has since supplemented with IRMS. IRMS measures the ratio of carbon-13 to carbon-12 in urinary testosterone metabolites. Because synthetic testosterone is derived from plant sterols with a different isotopic signature than endogenous testosterone, IRMS can confirm exogenous use even when the T/E ratio is within normal range [12].

A 2004 paper in Clinical Chemistry demonstrated that IRMS correctly identified exogenous testosterone administration in 100% of subjects given a single 100 mg testosterone enanthate injection, with detection windows extending to 22 days post-dose [17]. A 200 mg or higher dose extends that window further.

The Biogenesis suspension in 2014 relied not on a positive urine test but on documentary evidence: text messages, ledgers, and witness testimony. That precedent matters for understanding how anti-doping enforcement has moved beyond biological samples alone.

Branded vs. Compounded: A Side-by-Side Summary

| Feature | Branded (e.g., Depo-Testosterone) | Compounded (503A/503B) | |---|---|---| | FDA approval | Yes, full NDA | No | | Potency assurance | USP 90 to 110% | Variable (68 to 128% in studies) | | Sterility testing | cGMP mandatory | Required but not FDA-audited for 503A | | Dose flexibility | Limited to labeled strengths | High | | Cost (approx.) | $120, $180 per 10 mL vial | $40, $80 per 10 mL vial | | Insurance coverage | Generally covered | Rarely covered | | Available formulations | IM, SC, gel, nasal, patch | IM, SC, cream, troche, sublingual |

FAQ